Organon & Co (OGN) Q3 2025 Earnings Call Highlights: Strong Biosimilars Performance Amidst ... [Yahoo! Finance]
Organon & Co. (OGN)
Company Research
Source: Yahoo! Finance
Adjusted Gross Margin: 60.3% for the third quarter. Women's Health Franchise: Declined 4% at constant currency; Nexplanon sales were $223 million. Biosimilars: Hadlima up 63% ex-FX globally through September. Free Cash Flow: $813 million year-to-date before one-time costs. Net Leverage: Approximately 4.2x as of September 30. Full Year Revenue Guidance: Revised to $6.2 billion to $6.25 billion. Interest Expense: Estimated at $510 million for full year 2025. Non-GAAP Tax Rate: Estimated to be in the range of 22.5% to 24.5% for 2025. Warning! GuruFocus has detected 7 Warning Signs with OGN. Is OGN fairly valued? Test your thesis with our free DCF calculator. Release Date: November 10, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Organon & Co ( NYSE:OGN ) reported third quarter revenue of $1.6 billion and an adjusted EBITDA of $518 million, representing a margin of 32.3%. The company's
Show less
Read more
Impact Snapshot
Event Time:
OGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGN alerts
High impacting Organon & Co. news events
Weekly update
A roundup of the hottest topics
OGN
News
- Organon & Co. (NYSE:OGN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Organon & Co. (NYSE:OGN) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=OGN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</aMarketBeat
- Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026Business Wire
- Organon Completes Divestiture of JADA® System to LaborieBusiness Wire
- Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg RadiopaqueBusiness Wire
OGN
Earnings
- 11/10/25 - Beat
OGN
Sec Filings
- 1/16/26 - Form 4/A
- 11/17/25 - Form 4
- 11/17/25 - Form 4
- OGN's page on the SEC website